



UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION
WASHINGTON, DC 20580

April 20, 2016

Alicja Pachwicewicz
State of Washington
Submission No. 00001

Re: *In the Matter of Lupin Ltd., a limited liability corporation; Gavis Pharmaceuticals LLC, a limited liability corporation; and Novel Laboratories, Inc., a corporation; File No. 151-0202, Docket No. C-4566*

Dear Ms. Pachwicewicz:

ment on the public record pursuant to Rule 4.9(b)(6)(ii) of the Commission's
C.F.R. § 4.9(b)(6)(ii).

ion conducted its non-public review of the above-captioned matter pursuant
Section 7 of the Clayton Act, 15 U.S.C. § 18, and Section 5 of the Federal
ct, 15 U.S.C § 45. As such, the Commission has jurisdiction only to
are required to fix the competitive concerns . After careful consideration of your comment, the Commission has determined th
public interest would best be served by issuing the Decision and Order in final form without
modification. A copy of the final Decision and Order is enclosed for your information. Relevant
materials also are available from the Commission's website at www.ftc.gov.

It helps the Commission's analysis to hear from a variety of sources in its work on
antitrust and consumer protection issues, and we appreciate your interest in this matter.

By direction of the Commission.

April J. Tabor
Acting Secretary